For example, KRAS is most commonly mutated in the Ras family in pancreas (60–90%), colorectal (30–50%), and lung (15–30%) adenocarcinomas, while NRAS has the highest mutation rate in melanoma (15–30%) and HRAS in head and neck cancer (6%) [1, 7]. This evidence concerns the gene HRAS and head and neck cancer.